---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-057460"
form_type: "8-K"
ticker: "CLRB"
cik: "0001279704"
company_name: "Cellectar Biosciences, Inc."
filed_at: "2026-05-08T23:59:59+00:00"
generated_at: "2026-05-14T19:51:24.363006+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Cellectar raises ~$35M via stock/warrant offering; reports positive 12-mo Phase 2b WM data

## Summary
- Gross proceeds ~$35M; issued 1.6M registered shares, 2.1M unregistered, and warrants for 9.5M+13.2M shares.
- Phase 2b CLOVER WaM: 83.6% ORR, 61.8% MRR, median DoR 17.8 months in r/r WM.
- BTKi-exposed: 64.1% MRR, median PFS 15.9 mo; BTKi-refractory: 63.6% MRR, median PFS 14.8 mo.
- Nantahala gets board seat; warrants exercisable upon stockholder approval at $2.65.
- Proceeds to support Phase 3 trial of iopofosine I 131 for Waldenström macroglobulinemia.

## SEC filing metadata
- accession: 0001104659-26-057460
- form_type: 8-K
- ticker: CLRB
- cik: 0001279704
- company_name: Cellectar Biosciences, Inc.
- filed_at: 2026-05-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1279704/000110465926057460/0001104659-26-057460-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1279704/000110465926057460/tm2613728d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-057460
- JSON: https://secwatch.observer/filing/0001104659-26-057460.json
- Plain text: https://secwatch.observer/filing/0001104659-26-057460.txt

## Key facts
- Material Agreements
  Cellectar Biosciences, Inc. entered into Management Purchase Agreement with certain members of the executive management team of the Company (effective 2026-05-04).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain members of the executive management team of the Company
  - Effective: 2026-05-04
  source text: pursuant to an additional securities purchase agreement with certain members of the executive management team of the Company (the “Management Purchase Agreement”
  evidence_url: https://www.sec.gov/Archives/edgar/data/1279704/000110465926057460/0001104659-26-057460-index.htm
- Material Agreements
  Cellectar Biosciences, Inc. entered into Investor Purchase Agreement with certain institutional investors (effective 2026-05-04).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain institutional investors
  - Effective: 2026-05-04
  source text: On May 4, 2026, Cellectar Biosciences, Inc., a Delaware corporation (the “Company”) entered into a securities purchase agreement with certain institutional investors (the “Investor Purchaser Agreement”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1279704/000110465926057460/0001104659-26-057460-index.htm
- Material Agreements
  Cellectar Biosciences, Inc. entered into Placement Agency Agreement with Ladenburg Thalmann & Co. Inc. (effective 2026-05-04).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Ladenburg Thalmann & Co. Inc.
  - Effective: 2026-05-04
  source text: on May 4, 2026, the Company entered into a placement agency agreement (the “Placement Agency Agreement”) with Ladenburg Thalmann & Co. Inc. (the “Placement Agent”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1279704/000110465926057460/0001104659-26-057460-index.htm
- Material Agreements
  Cellectar Biosciences, Inc. entered into Registration Rights Agreement with certain investors (effective 2026-05-04).
  - Action: entry
  - Counterparty: certain investors
  - Effective: 2026-05-04
  source text: on May 4, 2026, the Company entered into a registration rights agreement (the “Registration Rights Agreement”) with certain investors
  evidence_url: https://www.sec.gov/Archives/edgar/data/1279704/000110465926057460/0001104659-26-057460-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.